Video – Clinical Trial Results with Steroid Refractory aGVHD ... | 合法藥品大搜索

Onscreen text and narrator: For Patients With Steroid-Refractory Acute Graft-Versus-Host Disease: The Results of a Clinical Trial With Jakafi® (ruxolitinib)

Onscreen text and narrator: Jakafi® (ruxolitinib) is the first and only prescription medicine approved by the FDA to treat adults and children 12 years of age and older with acute graft-versus-host disease (GVHD) who have taken corticosteroids and they did not work well enough.

Important Safety Information is discussed later in this video.

Onscreen text and narrator: This video is intended for informational use only and is not medical advice. Your Healthcare Professional is the best source for treatment-related questions and medical advice.

Emily: Hi. I’m Emily Knight, an oncology clinical nurse educator for Incyte. For more than 14 years prior to joining Incyte, I worked with patients who had cancer, as well as patients who had stem cell transplants, including those who ...